{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:06:51Z","timestamp":1790888811190,"version":"4.1.0"},"reference-count":93,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2019,9,3]]},"DOI":"10.1001\/jama.2019.11885","type":"journal-article","created":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T20:54:20Z","timestamp":1567544060000},"page":"857","source":"Crossref","is-referenced-by-count":175,"title":["Medication Use to Reduce Risk of Breast Cancer"],"prefix":"10.1001","volume":"322","author":[{"name":"US Preventive Services Task Force","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas K.","family":"Owens","sequence":"additional","affiliation":[{"name":"Veterans Affairs Palo Alto Health Care System, Palo Alto, California"},{"name":"Stanford University, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina W.","family":"Davidson","sequence":"additional","affiliation":[{"name":"Feinstein Institute for Medical Research at Northwell Health, Manhasset, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex H.","family":"Krist","sequence":"additional","affiliation":[{"name":"Fairfax Family Practice Residency, Fairfax, Virginia"},{"name":"Virginia Commonwealth University, Richmond"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Barry","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Cabana","sequence":"additional","affiliation":[{"name":"University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron B.","family":"Caughey","sequence":"additional","affiliation":[{"name":"Oregon Health & Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chyke A.","family":"Doubeni","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"John W.","family":"Epling","sequence":"additional","affiliation":[{"name":"Virginia Tech Carilion School of Medicine, Roanoke"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Kubik","sequence":"additional","affiliation":[{"name":"Temple University, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Seth","family":"Landefeld","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol M.","family":"Mangione","sequence":"additional","affiliation":[{"name":"University of California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori","family":"Pbert","sequence":"additional","affiliation":[{"name":"University of Massachusetts Medical School, Worcester"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Silverstein","sequence":"additional","affiliation":[{"name":"Boston University, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Wen","family":"Tseng","sequence":"additional","affiliation":[{"name":"University of Hawaii, Honolulu"},{"name":"Pacific Health Research and Education Institute, Honolulu, Hawaii"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John B.","family":"Wong","sequence":"additional","affiliation":[{"name":"Tufts University School of Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"key":"jus190016r4","article-title":"Medication use for the risk reduction of primary breast cancer in women: updated evidence report and systematic review for the US Preventive Services Task Force","author":"Nelson","journal-title":"JAMA"},{"issue":"17","key":"jus190016r6","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1200\/JCO.2010.33.0258","article-title":"Benefit\/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older.","volume":"29","author":"Freedman","year":"2011","journal-title":"J Clin Oncol"},{"issue":"19","key":"jus190016r7","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1093\/jnci\/dji290","article-title":"Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma.","volume":"97","author":"Travis","year":"2005","journal-title":"J Natl Cancer Inst"},{"issue":"23","key":"jus190016r8","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"issue":"10021","key":"jus190016r11","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/S0140-6736(15)01129-0","article-title":"Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial.","volume":"387","author":"Forbes","year":"2016","journal-title":"Lancet"},{"key":"jus190016r12","article-title":"Toxicity of extended adjuvant therapy with aromatase inhibitors in early breast cancer: a systematic review and meta-analysis","author":"Goldvaser","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"jus190016r13","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1093\/jnci\/djk049","article-title":"Long-term results of tamoxifen prophylaxis for breast cancer\u201496-month follow-up of the randomized IBIS-I trial.","volume":"99","author":"Cuzick","year":"2007","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"jus190016r14","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1093\/jnci\/djk050","article-title":"Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial.","volume":"99","author":"Powles","year":"2007","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"jus190016r15","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S1470-2045(14)71171-4","article-title":"Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial.","volume":"16","author":"Cuzick","year":"2015","journal-title":"Lancet Oncol"},{"issue":"4","key":"jus190016r16","doi-asserted-by":"publisher","first-page":"279","DOI":"10.7326\/M15-2886","article-title":"Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement.","volume":"164","author":"Siu","year":"2016","journal-title":"Ann Intern Med"},{"issue":"1","key":"jus190016r21","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ypmed.2004.09.041","article-title":"Factors affecting breast cancer risk reduction practices among California physicians.","volume":"41","author":"Kaplan","year":"2005","journal-title":"Prev Med"},{"issue":"9","key":"jus190016r22","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1089\/jwh.2014.4742","article-title":"Use of the Gail model and breast cancer preventive therapy among three primary care specialties.","volume":"23","author":"Corbelli","year":"2014","journal-title":"J Womens Health (Larchmt)"},{"issue":"20","key":"jus190016r23","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1001\/archinte.166.20.2260","article-title":"Prescription of tamoxifen for breast cancer prevention by primary care physicians.","volume":"166","author":"Armstrong","year":"2006","journal-title":"Arch Intern Med"},{"issue":"4","key":"jus190016r24","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1093\/annonc\/mdv590","article-title":"Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysis.","volume":"27","author":"Smith","year":"2016","journal-title":"Ann Oncol"},{"issue":"3","key":"jus190016r25","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s10549-009-0618-4","article-title":"Women\u2019s decisions regarding tamoxifen for breast cancer prevention: responses to a tailored decision aid.","volume":"119","author":"Fagerlin","year":"2010","journal-title":"Breast Cancer Res Treat"},{"issue":"10","key":"jus190016r26","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1002\/(ISSN)1097-0142","article-title":"Preferences of Women Evaluating Risks of Tamoxifen (POWER) study of preferences for tamoxifen for breast cancer risk reduction.","volume":"103","author":"Melnikow","year":"2005","journal-title":"Cancer"},{"issue":"2","key":"jus190016r27","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s10549-005-6932-6","article-title":"How should we inform women at higher risk of breast cancer about tamoxifen? an approach with a decision guide.","volume":"94","author":"McKay","year":"2005","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"jus190016r28","first-page":"365","article-title":"\u201cI\u2019m going to die of something anyway\u201d: women\u2019s perceptions of tamoxifen for breast cancer risk reduction.","volume":"15","author":"Paterniti","year":"2005","journal-title":"Ethn Dis"},{"issue":"3","key":"jus190016r29","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s10549-011-1450-1","article-title":"Women\u2019s interest in taking tamoxifen and raloxifene for breast cancer prevention: response to a tailored decision aid.","volume":"127","author":"Fagerlin","year":"2011","journal-title":"Breast Cancer Res Treat"},{"issue":"24","key":"jus190016r30","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1093\/jnci\/81.24.1879","article-title":"Projecting individualized probabilities of developing breast cancer for white females who are being examined annually.","volume":"81","author":"Gail","year":"1989","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"jus190016r31","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1111\/tbj.2007.13.issue-4","article-title":"Diagnostic accuracy of the Gail model in the Black Women\u2019s Health Study.","volume":"13","author":"Adams-Campbell","year":"2007","journal-title":"Breast J"},{"issue":"17","key":"jus190016r32","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1093\/jnci\/djj332","article-title":"Projecting absolute invasive breast cancer risk in white women with a model that includes mammographic density.","volume":"98","author":"Chen","year":"2006","journal-title":"J Natl Cancer Inst"},{"issue":"18","key":"jus190016r33","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1093\/jnci\/91.18.1541","article-title":"Validation studies for models projecting the risk of invasive and total breast cancer incidence.","volume":"91","author":"Costantino","year":"1999","journal-title":"J Natl Cancer Inst"},{"issue":"23","key":"jus190016r34","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1093\/jnci\/djm223","article-title":"Projecting individualized absolute invasive breast cancer risk in African American women.","volume":"99","author":"Gail","year":"2007","journal-title":"J Natl Cancer Inst"},{"issue":"12","key":"jus190016r35","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1093\/jnci\/djr154","article-title":"Projecting individualized absolute invasive breast cancer risk in Asian and Pacific Islander American women.","volume":"103","author":"Matsuno","year":"2011","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"jus190016r36","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1093\/jnci\/93.5.358","article-title":"Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention.","volume":"93","author":"Rockhill","year":"2001","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"jus190016r37","doi-asserted-by":"publisher","first-page":"337","DOI":"10.7326\/0003-4819-148-5-200803040-00004","article-title":"Using clinical factors and mammographic breast density to estimate breast cancer risk: development and validation of a new predictive model.","volume":"148","author":"Tice","year":"2008","journal-title":"Ann Intern Med"},{"issue":"17","key":"jus190016r38","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1093\/jnci\/djj331","article-title":"Prospective breast cancer risk prediction model for women undergoing screening mammography.","volume":"98","author":"Barlow","year":"2006","journal-title":"J Natl Cancer Inst"},{"issue":"28","key":"jus190016r39","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.1200\/JCO.2015.60.8869","article-title":"Breast density and benign breast disease: risk assessment to identify women at high risk of breast cancer.","volume":"33","author":"Tice","year":"2015","journal-title":"J Clin Oncol"},{"issue":"10","key":"jus190016r40","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1093\/aje\/152.10.950","article-title":"Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses\u2019 Health Study.","volume":"152","author":"Colditz","year":"2000","journal-title":"Am J Epidemiol"},{"issue":"9","key":"jus190016r41","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/S0895-4356(03)00124-0","article-title":"Breast cancer risk prediction with a log-incidence model: evaluation of accuracy.","volume":"56","author":"Rockhill","year":"2003","journal-title":"J Clin Epidemiol"},{"issue":"21","key":"jus190016r42","doi-asserted-by":"publisher","first-page":"4944","DOI":"10.1002\/cncr.25386","article-title":"Evaluation of a breast cancer risk prediction model expanded to include category of prior benign breast disease lesion.","volume":"116","author":"Tamimi","year":"2010","journal-title":"Cancer"},{"issue":"3","key":"jus190016r43","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1093\/jnci\/djh025","article-title":"Risk factors for breast cancer according to estrogen and progesterone receptor status.","volume":"96","author":"Colditz","year":"2004","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"jus190016r44","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1002\/(ISSN)1097-0258","article-title":"A breast cancer prediction model incorporating familial and personal risk factors.","volume":"23","author":"Tyrer","year":"2004","journal-title":"Stat Med"},{"issue":"11","key":"jus190016r45","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1136\/jmg.40.11.807","article-title":"Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme.","volume":"40","author":"Amir","year":"2003","journal-title":"J Med Genet"},{"issue":"22","key":"jus190016r46","doi-asserted-by":"publisher","first-page":"3591","DOI":"10.1200\/JCO.2010.28.0784","article-title":"Evaluation of the Tyrer-Cuzick (International Breast Cancer Intervention Study) model for breast cancer risk prediction in women with atypical hyperplasia.","volume":"28","author":"Boughey","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"jus190016r47","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s13058-015-0653-5","article-title":"Mammographic density adds accuracy to both the Tyrer-Cuzick and Gail breast cancer risk models in a prospective UK screening cohort","volume":"17","author":"Brentnall","year":"2015","journal-title":"Breast Cancer Res"},{"issue":"22","key":"jus190016r48","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1093\/jnci\/djm224","article-title":"Predicting risk of breast cancer in postmenopausal women by hormone receptor status.","volume":"99","author":"Chlebowski","year":"2007","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"jus190016r49","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1097\/01.cej.0000130014.83901.53","article-title":"Contribution of three components to individual cancer risk predicting breast cancer risk in Italy.","volume":"13","author":"Boyle","year":"2004","journal-title":"Eur J Cancer Prev"},{"issue":"23","key":"jus190016r50","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1093\/jnci\/djj463","article-title":"Gail model for prediction of absolute risk of invasive breast cancer: independent evaluation in the Florence-European Prospective Investigation Into Cancer and Nutrition cohort.","volume":"98","author":"Decarli","year":"2006","journal-title":"J Natl Cancer Inst"},{"issue":"13","key":"jus190016r51","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1093\/jnci\/djr172","article-title":"Risk factor modification and projections of absolute breast cancer risk.","volume":"103","author":"Petracci","year":"2011","journal-title":"J Natl Cancer Inst"},{"issue":"9336","key":"jus190016r52","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/S0140-6736(02)09962-2","article-title":"First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial.","volume":"360","author":"Cuzick","year":"2002","journal-title":"Lancet"},{"issue":"18","key":"jus190016r53","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","article-title":"Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.","volume":"90","author":"Fisher","year":"1998","journal-title":"J Natl Cancer Inst"},{"issue":"21","key":"jus190016r54","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1093\/jnci\/93.21.1615","article-title":"Tamoxifen and depression: more evidence from the National Surgical Adjuvant Breast and Bowel Project\u2019s Breast Cancer Prevention (P-1) randomized study.","volume":"93","author":"Day","year":"2001","journal-title":"J Natl Cancer Inst"},{"issue":"9122","key":"jus190016r55","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/S0140-6736(98)85012-5","article-title":"Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial.","volume":"352","author":"Powles","year":"1998","journal-title":"Lancet"},{"issue":"9122","key":"jus190016r56","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S0140-6736(98)85011-3","article-title":"Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women.","volume":"352","author":"Veronesi","year":"1998","journal-title":"Lancet"},{"issue":"9","key":"jus190016r57","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1093\/jnci\/djk154","article-title":"Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy.","volume":"99","author":"Veronesi","year":"2007","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"jus190016r58","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1093\/jnci\/95.2.160","article-title":"Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women.","volume":"95","author":"Veronesi","year":"2003","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"jus190016r59","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1161\/01.CIR.0000154545.84124.AC","article-title":"Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial.","volume":"111","author":"Decensi","year":"2005","journal-title":"Circulation"},{"issue":"22","key":"jus190016r60","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1093\/jnci\/dji372","article-title":"Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.","volume":"97","author":"Fisher","year":"2005","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"jus190016r61","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1093\/annonc\/mdt244","article-title":"A phase-III prevention trial of low-dose tamoxifen in postmenopausal hormone replacement therapy users: the HOT study.","volume":"24","author":"DeCensi","year":"2013","journal-title":"Ann Oncol"},{"issue":"7","key":"jus190016r62","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1001\/jama.282.7.637","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial.","volume":"282","author":"Ettinger","year":"1999","journal-title":"JAMA"},{"issue":"23","key":"jus190016r63","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1001\/jama.281.23.2189","article-title":"The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial.","volume":"281","author":"Cummings","year":"1999","journal-title":"JAMA"},{"issue":"2","key":"jus190016r64","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1023\/A:1006478317173","article-title":"Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial.","volume":"65","author":"Cauley","year":"2001","journal-title":"Breast Cancer Res Treat"},{"issue":"7","key":"jus190016r65","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1001\/jama.287.7.847","article-title":"Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial.","volume":"287","author":"Barrett-Connor","year":"2002","journal-title":"JAMA"},{"issue":"8","key":"jus190016r66","doi-asserted-by":"publisher","first-page":"3609","DOI":"10.1210\/jcem.87.8.8750","article-title":"Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial.","volume":"87","author":"Delmas","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"jus190016r67","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/S8756-3282(03)00241-2","article-title":"Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial.","volume":"33","author":"Delmas","year":"2003","journal-title":"Bone"},{"issue":"4","key":"jus190016r68","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1097\/01.AOG.0000137349.79204.b8","article-title":"Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation.","volume":"104","author":"Grady","year":"2004","journal-title":"Obstet Gynecol"},{"issue":"8","key":"jus190016r69","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1359\/JBMR.040406","article-title":"Risk-benefit profile for raloxifene: 4-year data from the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial.","volume":"19","author":"Barrett-Connor","year":"2004","journal-title":"J Bone Miner Res"},{"issue":"9","key":"jus190016r70","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1111\/jgs.2004.52.issue-9","article-title":"Comparison of fracture, cardiovascular event, and breast cancer rates at 3 years in postmenopausal women with osteoporosis.","volume":"52","author":"Silverman","year":"2004","journal-title":"J Am Geriatr Soc"},{"issue":"9","key":"jus190016r71","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1185\/030079905X61839","article-title":"Safety assessment of raloxifene over eight years in a clinical trial setting.","volume":"21","author":"Martino","year":"2005","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"jus190016r72","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1097\/01.GME.0000151653.02620.89","article-title":"Vascular events in the Multiple Outcomes of Raloxifene Evaluation (MORE) trial: incidence, patient characteristics, and effect of raloxifene.","volume":"12","author":"Duvernoy","year":"2005","journal-title":"Menopause"},{"issue":"1","key":"jus190016r73","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1185\/030079904X18045","article-title":"Year-by-year analysis of cardiovascular events in the Multiple Outcomes of Raloxifene Evaluation (MORE) trial.","volume":"21","author":"Keech","year":"2005","journal-title":"Curr Med Res Opin"},{"issue":"9","key":"jus190016r74","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1359\/JBMR.050509","article-title":"Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study.","volume":"20","author":"Siris","year":"2005","journal-title":"J Bone Miner Res"},{"issue":"17","key":"jus190016r75","doi-asserted-by":"publisher","first-page":"5242","DOI":"10.1158\/1078-0432.CCR-06-0688","article-title":"Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer risk.","volume":"12","author":"Lippman","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"2","key":"jus190016r76","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa062462","article-title":"Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women.","volume":"355","author":"Barrett-Connor","year":"2006","journal-title":"N Engl J Med"},{"issue":"1","key":"jus190016r77","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1359\/jbmr.070904","article-title":"Effects of raloxifene on fracture risk in postmenopausal women: the Raloxifene Use for the Heart trial.","volume":"23","author":"Ensrud","year":"2008","journal-title":"J Bone Miner Res"},{"issue":"12","key":"jus190016r78","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1093\/jnci\/djn153","article-title":"Reduced incidence of invasive breast cancer with raloxifene among women at increased coronary risk.","volume":"100","author":"Grady","year":"2008","journal-title":"J Natl Cancer Inst"},{"issue":"23","key":"jus190016r79","doi-asserted-by":"publisher","first-page":"2742","DOI":"10.1001\/jama.295.23.joc60075","article-title":"Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.","volume":"295","author":"Land","year":"2006","journal-title":"JAMA"},{"issue":"23","key":"jus190016r80","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.1001\/jama.295.23.joc60074","article-title":"Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.","volume":"295","author":"Vogel","year":"2006","journal-title":"JAMA"},{"issue":"6","key":"jus190016r81","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1158\/1940-6207.CAPR-10-0076","article-title":"Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: preventing breast cancer.","volume":"3","author":"Vogel","year":"2010","journal-title":"Cancer Prev Res (Phila)"},{"issue":"14","key":"jus190016r82","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1200\/JCO.2013.51.2483","article-title":"Quality of life in MAP.3 (Mammary Prevention 3): a randomized, placebo-controlled trial evaluating exemestane for prevention of breast cancer.","volume":"32","author":"Maunsell","year":"2014","journal-title":"J Clin Oncol"},{"issue":"25","key":"jus190016r83","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1056\/NEJMoa1103507","article-title":"Exemestane for breast-cancer prevention in postmenopausal women","volume":"364","author":"Goss","year":"2011","journal-title":"N Engl J Med"},{"issue":"9922","key":"jus190016r84","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/S0140-6736(13)62292-8","article-title":"Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial","volume":"383","author":"Cuzick","year":"2014","journal-title":"Lancet"},{"issue":"13","key":"jus190016r85","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1016\/S1470-2045(14)71035-6","article-title":"Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial","volume":"15","author":"Sestak","year":"2014","journal-title":"Lancet Oncol"},{"issue":"2","key":"jus190016r86","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1200\/JCO.2015.63.4972","article-title":"Anastrozole-induced carpal tunnel syndrome: results from the International Breast Cancer Intervention Study II prevention trial.","volume":"34","author":"Spagnolo","year":"2016","journal-title":"J Clin Oncol"},{"issue":"10001","key":"jus190016r87","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S0140-6736(15)61074-1","article-title":"Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials.","volume":"386","author":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG)","year":"2015","journal-title":"Lancet"},{"issue":"10","key":"jus190016r88","first-page":"698","article-title":"Medications to decrease the risk for breast cancer in women: recommendations from the U.S. Preventive Services Task Force recommendation statement.","volume":"159","author":"Moyer","year":"2013","journal-title":"Ann Intern Med"},{"issue":"23","key":"jus190016r89","doi-asserted-by":"publisher","first-page":"2942","DOI":"10.1200\/JCO.2013.49.3122","article-title":"Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline.","volume":"31","author":"Visvanathan","year":"2013","journal-title":"J Clin Oncol"},{"issue":"3","key":"jus190016r91","doi-asserted-by":"publisher","first-page":"e110","DOI":"10.1097\/AOG.0000000000002296","article-title":"Practice Bulletin No. 182: hereditary breast and ovarian cancer syndrome.","volume":"130","author":"Committee on Practice Bulletins\u2013Gynecology, Committee on Genetics, Society of Gynecologic Oncology","year":"2017","journal-title":"Obstet Gynecol"},{"issue":"6","key":"jus190016r92","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1097\/01.AOG.0000450757.18294.cf","article-title":"Committee Opinion No. 601: tamoxifen and uterine cancer.","volume":"123","year":"2014","journal-title":"Obstet Gynecol"},{"key":"jus190016r3","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2019.5780","volume-title":"Medication Use for the Risk Reduction of Primary Breast Cancer in Women: A Systematic Review for the U.S. Preventive Services Task Force","author":"Nelson","year":"2019"},{"key":"jus190016r1","unstructured":"National Cancer Institute (NCI). SEER Cancer Stat Facts: Female Breast Cancer 2018. NCI website. https:\/\/seer.cancer.gov\/statfacts\/html\/breast.html. Published 2018. Accessed August 1, 2019."},{"key":"jus190016r2","unstructured":"American Cancer Society (ACS). Cancer Facts & Figures 2018. ACS website. https:\/\/www.cancer.org\/research\/cancer-facts-statistics\/all-cancer-facts-figures\/cancer-facts-figures-2018.html. Published 2018. Accessed August 1, 2019."},{"key":"jus190016r5","unstructured":"National Cancer Institute (NCI). The Breast Cancer Risk Assessment Tool. NCI website. https:\/\/bcrisktool.cancer.gov\/. 2017. Accessed November 23, 2018."},{"key":"jus190016r9","unstructured":"American Cancer Society (ACS). Breast Cancer Facts & Figures 2017-2018. ACS website. https:\/\/www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/breast-cancer-facts-and-figures\/breast-cancer-facts-and-figures-2017-2018.pdf. 2017. Accessed August 1, 2019."},{"key":"jus190016r10","unstructured":"National Cancer Institute (NCI). BRCA Mutations: Cancer Risk and Genetic Testing. NCS website. https:\/\/www.cancer.gov\/about-cancer\/causes-prevention\/genetics\/brca-fact-sheet. 2018. Accessed November 16, 2018."},{"key":"jus190016r17","unstructured":"US Preventive Services Task Force (USPSTF). Recommendations for Primary Care Practice. USPSTF website. https:\/\/www.uspreventiveservicestaskforce.org\/Page\/Name\/recommendations. 2018. Accessed November 23, 2018."},{"key":"jus190016r18","unstructured":"PDQ\u00ae Screening and Prevention Editorial Board, National Cancer Institute (NCI). PDQ Breast Cancer Prevention (PDQ\u00ae)\u2014Patient Version. NCI website. https:\/\/www.cancer.gov\/types\/breast\/patient\/breast-prevention-pdq. Updated June 20, 2019. Accessed August 6, 2019."},{"key":"jus190016r19","unstructured":"Centers for Disease Control and Prevention (CDC). What can I do to reduce my risk of breast cancer? CDC website. https:\/\/www.cdc.gov\/cancer\/breast\/basic_info\/prevention.htm. September 11, 2018. Accessed August 2, 2019."},{"key":"jus190016r20","unstructured":"Breast Cancer Surveillance Consortium (BCSC). Breast Cancer Surveillance Consortium Risk Calculator. BCSC website. https:\/\/tools.bcsc-scc.org\/bc5yearrisk\/calculator.htm. 2015. Accessed November 23, 2018."},{"key":"jus190016r90","unstructured":"National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Breast Cancer Risk Reduction, Version 2. NCCN website. https:\/\/www.nccn.org\/professionals\/physician_gls\/default.aspx. 2018. Accessed August 1, 2019."},{"key":"jus190016r93","unstructured":"American Academy of Family Physicians (AAFP). Clinical preventive service recommendation: medications to reduce breast cancer risk. AAFP website. https:\/\/www.aafp.org\/patient-care\/clinical-recommendations\/all\/breast-cancer-medication.html. Accessed August 2, 2019."}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2749221\/jama_owens_2019_us_190016.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,11]],"date-time":"2019-10-11T18:41:17Z","timestamp":1570819277000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2749221"}},"subtitle":["US Preventive Services Task Force Recommendation Statement"],"short-title":[],"issued":{"date-parts":[[2019,9,3]]},"references-count":93,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2019.11885","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9,3]]}}}